Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'Nrti Backbone'
Nrti Backbone published presentations and documents on DocSlides.
Comparison of INSTI vs PI
by conchita-marotz
FLAMINGO. GS-236-0103. ACTG . A5257. WAVES. . De...
Comparison of NNRTI vs PI/r
by alexa-scheidler
EFV vs LPV/r vs EFV + LPV/r . A5142. Mexican. . ...
Management of NRTI Resistance
by giovanna-bartolotta
David Spach, MD. Principal . Investigator, NW AET...
Switch a ATV/r 3TC Estudio ATLAS-M
by pamella-moone
ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N =...
HIV Treatment 101 C. Ryan Tomlin, Pharm.D., BCPS, AAHIVP
by Powerpixel
Clinical Pharmacist – HIV Medicine. Outline. Wha...
DTG vs LPV/r (DAWNING): Efficacy
by winnie
by Baseline NRTI Resistance . and Second-Line NRTI...
DTG-Based Regimens Are Active in INI-Naive Patients With a
by trish-goza
Jim Demarest. ,. 1. Mark Underwood,. 2. Marty S...
NRTI-sparing
by min-jolicoeur
SPARTAN. PROGRESS. NEAT001/ANRS 14. 3 . MODERN. R...
Crafting an ART Regimen for Initiation or Salvage:
by mitsue-stanley
Are NRTI’s Necessary?. Brian R. Wood, MD. Assis...
HIV Drug Resistance in Well-Resourced Settings
by faustina-dinatale
Vincent Marconi, . MD. Outline. Transmitted Drug ...
Switch to LPV/
by lindy-dunigan
r. + 3TC. OLE . Study. LPV/. r. bid + 3TC or FT...
Comparison of NRTI combinations
by tawny-fly
ZDV/3TC . vs. TDF + FTC. Study 934. ABC/3TC . vs...
NRTI-sparing
by liane-varnes
SPARTAN. PROGRESS. RADAR. NEAT001/ANRS 14. 3. A40...
Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine
by luanne-stotts
Chief, Division of Infectious Diseases. Weill Med...
Antiretroviral Updates:
by tatyana-admore
New Treatments for HIV. C. Ryan Tomlin, . Pharm.D...
Advances and Challenges in HIV Antiretroviral Therapy
by stefany-barnette
Camille Angle, Meagan Bardan, Hanna Schimjawicz a...
HIV Pharmacotherapy Focused Update
by yoshiko-marsland
Drew Lambert, . PharmD. lambertd@husson.edu. Huss...
Phase 2 of new ARVs Fostemsavir
by conchita-marotz
, . prodrug. of . temsavir. . (attachment inhib...
Joel E. Gallant, MD, MPH
by mastervisa
Medical Director, Specialty . Services. Southwest ...
Switch to LPV/ r + 3TC OLE
by susan2
Study. LPV/. r. bid + 3TC or FTC . qd. + NRTI. N ...
Meg Doherty MD MPH PhD 23 July 2018
by jordyn
WHO HQ. The role of DTG based regimens in first- a...
What’s new in the 2019 WHO Guidelines:
by elina
Dolutegravir based regimens in first- ad second-li...
Switching Antiretroviral Therapy (ART) in Your African American Patients: When and How
by taylor
Supported by an educational grant from Gilead Scie...
Dolutegravir vs. Raltegravir
by zoe
SPRING-2 Study. Dolutegravir. versus Raltegravir....
NRTI-sparing SPARTAN PROGRESS
by shepard237
RADAR. NEAT001/ANRS 14. 3 . A4001078. VEMAN. MODER...
Switch PI/R to ETR Etraswitch
by dustin869
Etraswitch. . Study. : Switch PI/r to ETR. Contin...
Load More...